Nandrolone Decanoate

Summary

Nandrolone Decanoate (CHEMBL1200946) is an approved small molecule; indicated across 4 conditions including hip fracture and hiv wasting syndrome.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 4 conditions
• Clinical trials: 9
• Chemistry: 428.6 Da · C28H44O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200946
Name	Nandrolone Decanoate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	9677
Molecular formula	C28H44O3
Molecular weight	428.6
InChIKey	JKWKMORAXJQQSR-MOPIKTETSA-N

SMILES: CCCCCCCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@H]34)C

IUPAC name: [(8R,9S,10R,13S,14S,17S)-13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl] decanoate

Also known as: Deca-durabolin, Nandrolone decanoate, Nandrolone decanoate ciii, SID29215336, Nandrolone Decanoate, NANDROLONE DECANOATE, SID170464711, SID144205191

Patent coverage: 720 distinct patent families (2,720 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Microtubule-associated protein tau, Prelamin-A/C, Ferritin light chain.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 4 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
MAPT	5.3	Potency	5012	nM	CHEMBL_ACT_4022061
MAPT	5	Potency	10000	nM	CHEMBL_ACT_4501867

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
hip fracture	2	MONDO:0005327	EFO:0003964
HIV wasting syndrome	1	MONDO:0005797	EFO:0007312

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
Not specified	3
PHASE4	2
PHASE2	2
PHASE1/PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06462482	PHASE4	NOT_YET_RECRUITING	Peri-Operative Testosterone Administration in Primary Hip Arthroscopy
NCT06608914	PHASE4	NOT_YET_RECRUITING	Peri-Operative Testosterone Administration in Primary Total Hip Arthroplasty
NCT05978206	PHASE2	RECRUITING	Study of the Effectiveness of Treatment of Sarcopenia With the Use of a Medicinal Product (Nandrolone), Comprehensive Physiotherapy and Diet
NCT02055456	PHASE1/PHASE2	COMPLETED	Nandrolone Decanoate in the Treatment of Telomeropathies
NCT03545347	PHASE2	COMPLETED	Physiotherapy, Nutritional Supplement and Anabolic Steroids in Rehabilitation of Patients With Hip Fracture.
NCT00000854	PHASE1	COMPLETED	A Study to Evaluate the Effect of Nandrolone Decanoate in Women With HIV-Associated Weight Loss
NCT00250536	Not specified	COMPLETED	Anabolic Steroids and Exercise in Hemodialysis Patients
NCT03263520	Not specified	COMPLETED	Impact of the Use of Nandrolone on the Treatment of Malnutrition Induced by Cancer
NCT05805553	Not specified	UNKNOWN	Anabolic Steroid and Propranolol in Paediatric Burn

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).